医学
间质细胞
结直肠癌
鉴定(生物学)
免疫疗法
签名(拓扑)
达沙替尼
肿瘤科
癌相关成纤维细胞
癌症研究
基因签名
内科学
后天抵抗
生物信息学
钥匙(锁)
计算生物学
癌症
文本挖掘
癌症免疫疗法
作者
Weichun Tang,Linlin Zhu,Qiang Li,Biao Gu,Pengpeng Xu,Nannan Wang,Shangshang Hu
标识
DOI:10.1097/js9.0000000000003825
摘要
BACKGROUND: Transforming growth factor-β (TGF-β) signaling shapes tumor biology and immunity, yet its clinical impact in colorectal cancer (CRC) is unclear. METHODS: 3000 CRC specimens integrating bulk, single-cell, and spatial transcriptomes plus proteomics were profiled. Single-sample gene-set enrichment scored TGF-β activity; consensus clustering defined subtypes. A 12-gene TGF-β-related risk signature (TGFRS) was built by machine learning and interpreted with SHapley Additive exPlanations. Key genes were validated in vitro and in vivo . Drug-sensitivity screening, molecular docking, and molecular-dynamics simulations nominated candidate inhibitors. RESULTS: High TGF-β scores or subtype C2 independently predicted poor survival and resistance to immune-checkpoint blockade. TGFRS outperformed 139 published signatures for prognosis and immunotherapy response and remained significant in multivariable models. Reticulocalbin-3 (RCN3) carried the greatest TGFRS weight and was restricted to cancer-associated fibroblasts (CAFs). RCN3-positive CAFs (RCN3⁺Fib) exhibited hyper-activated TGF-β signaling, neighbored tumor cells and M2 macrophages, and enhanced epithelial-mesenchymal transition, invasion, and M2-like polarization in coculture and xenografts. TGF-β induced RCN3 through RELB, creating a positive feedback loop. Among screened compounds, dasatinib showed the greatest sensitivity in RCN3⁺Fib. CONCLUSIONS: Comprehensive multi-omics mapping links heightened TGF-β activity and a distinct consensus-clustering subtype to unfavorable outcomes and immunotherapy resistance in CRC. The externally validated TGFRS offers a practical prognostic and predictive tool. RCN3⁺ CAFs constitute key stromal drivers, and dasatinib emerges as a repurposable agent to disrupt this axis, warranting clinical exploration.
科研通智能强力驱动
Strongly Powered by AbleSci AI